Developer of biosimilar theraputics
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. 

Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. 

Policies to help grow the biosimilars marketplace in the United States. 

Policies focused on improving cancer care through access to affordable treatments.
PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE
NATHANSON+HAUCK
601 13th Street NW, Suite 290 North, Washington, DC, 20005, US
MELANIE JAN NATHANSON MEGAN HAUCK MARSHALL